The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Momelotinib in patients with MF and anemia: Subgroup analysis of the SIMPLIFY-2 trial
|
The phase III SIMPLIFY-2 trial (NCT02101268) assessed momelotinib, a JAKi, vs BAT (88.5% continued ruxolitinib) in JAKi-experienced patients with MF.1 Results from this trial were previously reported by the MPN Hub. A post hoc descriptive analysis evaluated outcomes in two patient subgroups: patients with moderate-to-severe anemia, defined by baseline Hb <100 g/L, and patients who were not TI at baseline. Results from this analysis were published in Advances in Therapy by Harrison et al.1
|
| Key learnings |
|
Both patient subgroups showed superior anemia-related outcomes with momelotinib vs BAT; transfusion independence rates at Week 24 were higher in patients with baseline Hb <100 g/L (33.3% vs 12.8%) and in patients who were not TI at baseline (34.7% vs 3.0%). Additionally, mean Hb levels in both subgroups improved and remained higher with momelotinib, despite lower or comparable median transfusion rates through Week 24. |
|
Switching to momelotinib improved anemia management without compromising spleen volume reduction or symptom control; splenic response rates were 9.1% vs 5.1% in patients with Hb <100 g/L and 9.7% vs 3.0% in non-TI patients, while symptom response rates were 32.3% vs 2.6% in patients with Hb <100 g/L and 29.2% vs 0% in non-TI patients. |
|
Patients continuing BAT/ruxolitinib required additional anemia-supportive therapies such as ESAs; however, this approach provided limited anemia benefits and lower symptoms and spleen control compared with switching to momelotinib. |
|
These findings suggest that switching to momelotinib instead of continuing ruxolitinib and using ESAs or other supportive therapies may be a more effective strategy for JAKi-experienced patients with MF who have moderate-to-severe anemia or are non-TI. |
Abbreviations: BAT, best available therapy; ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; JAKi, Janus kinase inhibitor; MF, myelofibrosis; TI, transfusion-independent.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
